€1.75bn Health Work Programme Grant Announced
Last week, the European Commission published the main Work Programmes for Horizon Europe’s 2021-2022 grant funding. Outlining the objectives and specific topic areas that will receive a total of €14.7 billion in funding, the main mission for Horizon Europe in 2021-2022 is:
“Investments will help accelerate the green and digital transitions and will contribute to sustainable recovery from the coronavirus pandemic and to EU resilience against future crises.”
For those in the UK, or looking to collaborate within the UK, the European Commission Q&A on the UK's participation in Horizon Europe confirms that UK entities are eligible to apply.
In this week’s newsletter, Dragon Argent takes a detailed look at the Health Work Programme for any entrepreneurs / businesses who could benefit. We work closely with an expert grant consultant who can advise business on any specific enquiries off the back of the below.
The €1.75bn Health Work Programme has six sub-areas, known as destinations:
Staying healthy in a rapidly changing society (€289 million)
Living and working in a health-promoting environment (€350 million)
Tackling diseases and reducing disease burden (€490 million)
Ensuring access to innovative, sustainable and high-quality health care (€240 million)
Unlocking the full potential of new tools, technologies and digital solutions for a healthy society (€270 million)
Maintaining an innovative, sustainable and globally competitive health related industry (€113 million)
In the Health Work Programme, the deadlines foreseen depend on topic and are 21 Sept 2021, 1 Feb 2022 or 21 April 2022.
The European Commission will be holding a series of Information Days about Horizon Europe between 28 June and 9 July, with the Health Cluster Information Day scheduled for Friday 2 July.
The Innovative Medicines Initiative (IMI) has also launched its 23rd call for proposals covering 6 topics:
Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework
Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance.
A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
Optimal treatment for patients with solid tumours in Europe through artificial intelligence
Shortening the path to rare disease diagnosis by using new-born genetic screening and digital technologies
Behavioural model of factors affecting patient adherence
Entities based in the UK are also eligible to apply for IMI calls.
If you are working on developing a healthcare or innovative medicine solution, it could be worth investigating your eligibility for grant funding from the EU’s Horizon programme. As mentioned, Dragon Argent work with an expert grant consultant who can help advise on this. Please contact me on the details below for more information.
Categories
- (S)EIS Tax Relief
- Accountancy Best Practice
- Art and Luxury Assets
- Business Immigration
- Commercial Law
- Commercial Litigation
- Corporate Law
- Corporate Strategy
- EMI Share Option Scheme
- ESG Compliance
- Employment Law
- Fundraising Strategy
- Human Resources
- Intellectual Property
- Merger and Acquisition
- NFTs and Digital Trading
- R&D Tax Credits
- Startups & SME Advice
- Tax Advice
- UK Subsidiary
Dragon Argent are delighted to announce that it has advised the shareholders of Peabodys Coffee on its acquisition by a FTSE 100 company in the hospitality sector.